Clinical Research STUDIES at Central Regional Hospital

How to use this page:

The research studies at the Central Regional (formerly Dorothea Dix) CRU target chronic stages of psychotic disorders. Below are the names and brief descriptions of each study.  If you see a study that may apply to you, click on the link and get further details on the study and contact information.

CONNECT Study - An investigational medication trial to treat impairments of thinking and memory in adults diagnosed with schizophrenia

The purpose of this study is to determine the efficacy and safety of an investigational medication in improving cognition (thinking and memory) in adults diagnosed with schizophrenia who are taking antipsychotic monotherapy.  Read more >>

Ages: 18-65

CAMP Study – Clinical management of metabolic problems in patients with schizophrenia: switching to aripiprazole versus continued treatment with olanzapine, quetiapine or risperidone 

The purpose of this six-month study is to compare the effects of switching to aripiprazole versus continued treatment with olanzapine, quetipine or risperidone on the risk of cardiovascular disease. This study is conducted in conjunction with the NIMH Schizophrenia Trials.  Read more >>

Ages: 18-65

OTS Study - Oxytocin Treatment of Schizophrenia

This is a randomized, double-blind, placebo-controlled study to compare the effects of two weeks of daily administration of oxytocin vs. placebo on social cognition, paranoia and other psychotic symptoms, and social competence in patients with schizophrenia. This is a single-site pilot study for inpatients or outpatients, ages 18-55 years, meeting DSM-IV criteria for schizophrenia, paranoid or undifferentiated type, who have been diagnosed > 1 year, and on the same psychotropic medication(s) and dose(s) for at least one month.

Ages: 18-55

PEARL 2 - Studying the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia 

This is a randomized, inpatient, double-blind, parallel-group study designed to evaluate the safety and efficacy of treatment for 6 weeks with 2 doses of lurasidone HCl compared with placebo and olanzapine in acutely psychotic inpatients with chronic schizophrenia. The acute phase of the study is followed by a 6-month, outpatient, open-label extension phase.  Read more >>

PEARL LTSS - Long-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects with Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial

This is a randomized, double-blind, parallel-group study designed to evaluate the long-term safety, tolerability, and effectiveness of treatment for 12 months with lurasidone compared with risperidone in patients with chronic schizophrenia or schizoaffective disorder.  Read more >>

Ages: 18-75